Manuel Vázquez Carrera
Jefe de Grupo Senior
The researcher Manuel Vázquez Carrera graduated in Pharmacy in 1990 from the University of Barcelona and received his Doctor of Pharmacology degree from the University of Barcelona in 1994.
Between 1996 and 2001 he spent a postdoctoral stay at the Institut de Biologie Animale de la Université de Lausanne where he studied the mechanisms of action of the nuclear receptor PPARα.
In 1997 he got a position of full professor at the University of Barcelona and since 2017 he has been full professor of the same university. However, he is a principal researcher at CIBERDEM.
He is currently leading the research group Pharmacological Targets for Inflammation and Metabolic Diseases, where he studies the mechanisms involved in the relationship between inflammation and the development of insulin resistance and diabetic cardiomyopathy.
Professional network profiles
Last Publications
- Zhang M, Bagán A, Martínez D, Barroso E, Palomer FX, Vázquez S, Escolano C and Vazquez M Design and Synthesis of AMPK Activators and GDF15 Inducers. Molecules . 28(14): .
- Barroso E, Montori M, Wahli W, Palomer FX and Vazquez M Striking a gut-liver balance for the antidiabetic effects of metformin TRENDS IN PHARMACOLOGICAL SCIENCES . 44(7): 457-473.
- Aguilar-Recarte D, Barroso E, Zhang M, Rada P, Pizarro J, Peña L, Palomer FX, Valverde ÁM, Wahli W and Vazquez M A positive feedback loop between AMPK and GDF15 promotes metformin antidiabetic effects. PHARMACOLOGICAL RESEARCH . 187: 106578-106578.
News
-
Metformin, key drug in the battle against type 2 Diabetes, reveals its secrets in a new study
Dr. Manuel Vázquez-Carrera, Institut de Recerca Sant Joan de Déu (IRSJD) and professor from the Faculty of Pharmacy and Food Sciences of the University of Barcelona, leads this new study on metformin, one of the most prescribed drugs for treating type 2 diabetes mellitus.
-
The most common type 2 diabetes drug needs the action of a cellular-stress-response protein to make effect
Metformin, the most prescribed drug for treating diabetes mellitus, known as type 2 diabetes, requires the presence of the growth differentiation factor 15 (GDF15) -a protein whose expression increases in response to cellular stress- to present its antidiabetic effects.
-
CDF15 cytokine, a promising therapeutic target against type 2 diabetes
A team led by Dr. Manuel Vázquez-Carrera, from the Institut de Recerca Sant Joan de Déu and professor Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine (IBUB) of the UB, has conducted a review study on the Growth Differentiation Factor 15 (GDF15) -a protein expressed under physiological stress conditions- and its potential impact on the treatment for type 2 diabetes.